Premium
O1–04–03: Amyloid burden in ageing subjects with and without cognitive decline
Author(s) -
Villemagne Victor L.,
Pike Kerryn,
Maruff Paul,
Ng Steven,
Savage Greg,
Darby David,
Cowie Tiffany F.,
Tochon-Danguy Henri J.,
O'Keefe Graeme,
Masters Colin L.,
Rowe Christopher C.
Publication year - 2007
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2007.04.079
Subject(s) - cognitive decline , pittsburgh compound b , ageing , gerontology , population , medicine , california verbal learning test , psychology , recall , cognition , dementia , disease , audiology , verbal memory , psychiatry , environmental health , cognitive psychology
subjects (MMSE 24 3, CDR 1) and 5 HC (MMSE 28) underwent PET imaging over 3 hours after injection of 300 MBq of the F-ligand. Distribution volume ratios (DVR) were calculated through graphical analysis using the cerebellum as input function. Results: All AD subjects showed neocortical binding, greatest in the precuneus/posterior cingulate and frontal cortex, followed by lateral temporal and parietal, with relative sparing of sensorimotor cortex. HC showed no binding in cortical or subcortical grey matter and their scans were clearly distinguishable from AD subjects. Cerebellar cortex showed no retention in either group. Significantly higher neocortical DVRs were observed in AD (1.84 0.20) when compared with HC (1.3 0.17, p 0.009). Cortical uptake to cerebellar cortex ratio (SUVR) at 90-120 minutes post-injection gave similar results to DVR. Conclusions: Our results show that A burden can be quantified in AD with a novel F-18 labelled PET ligand. The pattern of binding closely matches that reported with C-PIB. This ligand may permit wide application of amyloid imaging by centralized production and distribution not possible with a C-11 labelled A ligand.